Crossmark

Promoting de-implementation of inappropriate antimicrobial use in cardiac device procedures by expanding audit and feedback: protocol for hybrid III type effectiveness/implementation quasi-experimental study

Crossref DOI link: https://doi.org/10.1186/s13012-022-01186-8

Published Online: 2022-01-29

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Branch-Elliman, Westyn https://orcid.org/0000-0002-9658-5124
Lamkin, Rebecca

Shin, Marlena

Mull, Hillary J.

Epshtein, Isabella

Golenbock, Samuel

Schweizer, Marin L.

Colborn, Kathryn

Rove, Jessica

Strymish, Judith M.

Drekonja, Dimitri

Rodriguez-Barradas, Maria C.

Xu, Teena Huan

Elwy, A. Rani
Funding

Funding for this research was provided by:

Health Services Research and Development (IIR 20-076)
License Information

Text and Data Mining valid from 2022-01-29

Version of Record valid from 2022-01-29
More Information

Article History

Received: 8 December 2021

Accepted: 3 January 2022

First Online: 29 January 2022

Declarations

:

: Not applicable.

: Not applicable.

: WBE was the site PI of a COVID-19 therapeutics trial funded by Gilead Sciences (funds to institution). WBE is a paid expert witness for DLA Piper, LLC, Medtronic, and CRICO. All other authors report no competing interest.The views expressed are those of the authors and do not necessarily represent those of the US Federal Government or the Department of Veterans Affairs.

Document is current

Any future updates will be listed below